Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second dasatinib-assisted TKI discontinuation attempt in chronic myeloid leukemia after prior failed stop
NL-OMON46534Recruiting
- Sponsor
- Akademiska sjukhuset
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dasatinib in chronic myelogenous leukemia (CML), sponsored by Akademiska sjukhuset. Primary endpoints: Maintenance of major molecular remission at 6 months after second TKI discontinuation and Maintenance of major molecular remission at 12 months after second TKI discontinuation. Started Nov 2018; status: recruiting.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON46534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46534.